Gilead is committing $50m to a drug discovery partnership with Tony Johnson , which has developed the Kidney Goldfinch Bio of genetics and clinical data regarding the kidney. Gilead has provided $50m in upfront cash, along with $50m for equity and $ 54 m to support research into diabetic kidney disease. Goldfinch CEO Tony Johnson said the start-up will consider launching an IPO once it is closer to proof of concept data for new drugs.
Gilead is committing $109m to a drug discovery partnership with Goldfinch Bio, which has developed the Kidney Genome Atlas of genetics and clinical data regarding the kidney. Gilead has provided $50m in upfront cash, along with $5m for equity and $54m to support research into diabetic kidney disease. Goldfinch CEO Tony Johnson said the start-up will consider launching an IPO once it is closer to proof of concept data for new drugs.